CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Subscription Receivable	Receivable from Shareholder	Accumulated Deficit	Previously Reported	Previously Reported Common Stock	Previously Reported Additional Paid-In Capital	Previously Reported Subscription Receivable	Previously Reported Receivable from Shareholder	Previously Reported Accumulated Deficit	Revision of Prior Period, Adjustment	Revision of Prior Period, Adjustment Common Stock	Revision of Prior Period, Adjustment Additional Paid-In Capital	Revision of Prior Period, Adjustment Subscription Receivable	Revision of Prior Period, Adjustment Receivable from Shareholder	Revision of Prior Period, Adjustment Accumulated Deficit
Balance as of beginning of period (in shares) at Dec. 31, 2022	0						32,575,043						(32,575,043)
Balance as of beginning of period at Dec. 31, 2022	$ 0						$ 33						$ (33)
Balance as of end of period (in shares) at Jun. 30, 2023	0
Balance as of end of period at Jun. 30, 2023	$ 0
Balance as of beginning of period (in shares) at Dec. 31, 2022		13,303,795						0						13,303,795
Beginning balance at Dec. 31, 2022	1,563	$ 1	$ 80,738	$ 0	$ 0	$ (79,176)	$ 1,563	$ 0	$ 80,706	$ 0	$ 0	$ (79,176)	$ 0	$ 1	$ 32	$ 0	$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	2,240		2,240
Conversion of liability classified warrants to equity pursuant to sequencing policy	0
Exercise of common stock options (in shares)		12,867
Exercise of common stock options	12		12
Net loss	(16,171)					(16,171)
Balance as of ending of period (in shares) at Jun. 30, 2023		13,316,662
Ending balance at Jun. 30, 2023	$ (12,356)	$ 1	82,990	0	0	(95,347)
Balance as of beginning of period (in shares) at Mar. 31, 2023	0						32,602,843						(32,602,843)
Balance as of beginning of period at Mar. 31, 2023	$ 0						$ 33						$ (33)
Balance as of end of period (in shares) at Jun. 30, 2023	0
Balance as of end of period at Jun. 30, 2023	$ 0
Balance as of beginning of period (in shares) at Mar. 31, 2023		13,315,149						0						13,315,149
Beginning balance at Mar. 31, 2023	(5,497)	$ 1	82,000	0	0	(87,498)	$ (5,497)	$ 0	$ 81,968	$ 0	$ 0	$ (87,498)	$ 0	$ 1	$ 32	$ 0	$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	982		982
Exercise of common stock options (in shares)		1,513
Exercise of common stock options	8		8
Net loss	(7,849)					(7,849)
Balance as of ending of period (in shares) at Jun. 30, 2023		13,316,662
Ending balance at Jun. 30, 2023	$ (12,356)	$ 1	82,990	0	0	(95,347)
Balance as of beginning of period (in shares) at Dec. 31, 2023	0
Balance as of beginning of period at Dec. 31, 2023	$ 0
Balance as of end of period (in shares) at Jun. 30, 2024	0
Balance as of end of period at Jun. 30, 2024	$ 0
Balance as of beginning of period (in shares) at Dec. 31, 2023		21,888,976
Beginning balance at Dec. 31, 2023	(58,693)	$ 2	121,727	(17,792)	(500)	(162,130)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	2,214		2,214
Issuance of common stock in connection with financial instrument transactions (in shares)		3,882,156
Issuance of common stock in connection with financial instrument transactions	32	$ 1	31
Conversion of liability classified warrants to equity pursuant to sequencing policy	297		297
Forward purchase contract subscription	0		317	(317)
Amendment of forward purchase contracts	2,764			2,764
Settlement of forward purchase contracts	4,639			4,639
Settlement of receivable from shareholder	$ 500				500
Exercise of common stock options (in shares)	0
Net loss	$ (21,470)					(21,470)
Balance as of ending of period (in shares) at Jun. 30, 2024		25,771,132
Ending balance at Jun. 30, 2024	$ (69,717)	$ 3	124,586	(10,706)	0	(183,600)
Balance as of beginning of period (in shares) at Mar. 31, 2024	0
Balance as of beginning of period at Mar. 31, 2024	$ 0
Balance as of end of period (in shares) at Jun. 30, 2024	0
Balance as of end of period at Jun. 30, 2024	$ 0
Balance as of beginning of period (in shares) at Mar. 31, 2024		22,388,976
Beginning balance at Mar. 31, 2024	(55,055)	$ 2	122,844	(10,389)	0	(167,512)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	1,097		1,097
Issuance of common stock in connection with financial instrument transactions (in shares)		3,382,156
Issuance of common stock in connection with financial instrument transactions	32	$ 1	31
Conversion of liability classified warrants to equity pursuant to sequencing policy	297		297
Forward purchase contract subscription	0		317	(317)
Net loss	(16,088)					(16,088)
Balance as of ending of period (in shares) at Jun. 30, 2024		25,771,132
Ending balance at Jun. 30, 2024	$ (69,717)	$ 3	$ 124,586	$ (10,706)	$ 0	$ (183,600)